Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
DALLAS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the second quarter ended June 30, 2022.
- Vaxxinity expects to complete an end-of-treatment analysis of Part B in the second half of 2022.
- Phase 1 Part A trial of UB-312 in healthy volunteers results published in Movement Disorders, April 15, 2022 .
- Subsequent to the quarter-end, Vaxxinity began enrolling healthy volunteers into a Phase 1 clinical trial evaluating UB-313 for safety, tolerability, and immunogenicity.
- Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications.